跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2010-020171-23-DE
EUCTR2010-020171-23-DE进行中（未招募）不适用

A phase I/II study to evaluate safety, tolerability, pharmacokinetics and efficacy of resminostat (4SC-201) in combination with a second-line treatment in patients with k-ras mutated advanced colorectal carcinoma - SHORE-study

4SC AG0 个研究点目标入组 80 人开始时间: 2010年6月28日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
4SC AG
入组人数
80
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •- Signed informed consent must be obtained prior to any study specific procedure
  • •- Male or female patients, age = 18 years
  • •- Histologically or cytologically confirmed advanced stage colorectal carcinoma
  • •- Documented progression after precedent treatment according to RECIST criteria
  • •- Measurable lesion(s) as defined by modified RECIST criteria (Version 1.1)
  • •- ECOG performance status 0 – 2
  • •- Live expectancy of 12 weeks or more
  • •- Patients must have previously received treatment with 5-FU alone or in combination with other anti-tumor medications; the required prior treatment with 5-FU can be replaced by the previous use of the respective prodrug capecitabine (Xeloda® ).
  • •- Patients foreseen for chemotherapy with FOLFIRI in second or further line treatment
  • •- Patients must have adequate bone marrow reserve as evidenced by: Absolute neutrophil count (ANC) = 1,500/µl; Hb = 9 g/dL and platelet count = 75,000/µl
  • •- Patients must have a glomerular filtration rate according to MDRD formula of >°60 ml/min/1.73m2
  • •- Patients must have adequate hepatic function as evidenced by a serum bilirubin < 2.0 mg/dl and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels < 3x the ULN for the reference lab (< 5x the ULN if there is hepatic metastasis)
  • •- Patients must be recovered from the toxicities of any prior therapy, except polyneuropathy Grade = 1 and Hand-Foot-syndrome Grade = 1
  • •- Safe contraception in females of childbearing potential during the entire study using an established treatment with hormonal contraceptives for = 2 months prior to start of screening
  • •- For females of child bearing potential (without using hormonal contraceptives for at least 2 months prior to start of screening) a double contraception method is requested during the entire study meeting the criteria for an effective method of birth control. That means at least two effective birth control methods such as condoms, diaphragms or intra-uterine devices must be used. For the methods used, Pearl Index has to be < 1
  • •- Male subjects with partners of child-bearing potential are requested to use barrier contraception in addition to having their partner use another method of contraception during the trial and for three months after the last dose. Male subjects will also be advised to abstain from sexual intercourse with pregnant or lactating women, or to use condoms. For the methods used, Pearl Index has to be
  • •- Study participants must avoid excessive UV-radiation (sun bathes and solarium)
  • •and protect their eyes during exposure to direct sunlight
  • •Phase II (only those listed, that are in addition to or different to Phase I criteria):
  • •- Documented progression after first-line treatment according to RECIST criteria
  • •- k-ras mutation (which contraindicates EGFR inhibitor therapy, results from local
  • •pathology will be accepted for inclusion)
  • •- Patients must have previously received treatment with 5-FU alone or in
  • •combination with other anti-tumor medications (except irinotecan); the required
  • •prior treatment with 5-FU can be replaced by the previous use of the respective
  • •prodrug capecitabine (Xeloda® ).
  • •- Patients foreseen for 2nd line chemotherapy with FOLFIRI
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •- Patients who have received previous treatment with an HDAC inhibitor
  • •- Anticipation of need for a major surgical procedure or radiation therapy (RT) during the study
  • •- Patients who have received an investigational therapy within 4 weeks prior to first drug administration in the current study
  • •- Any gastrointestinal disorder that could interfere with the absorption of resminostat, such as active ulcerative colitis, Crohn’s disease, diabetic gastroparesis, or other syndromes characterized by malabsorption
  • •- Therapy with agents known to prolong the QT interval, such as certain antibiotics (i.e. erythromycin, clarithromycin), antidepressants (i.e. doxepin, amitryptilin) or neuroleptics (i.e. haloperidol, clozapin)
  • •- Patients who are homozygous for the UGT1A1 and characterized by the presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter ((TA)7TAA)
  • •- Therapy with strong CYP3A4 inhibitors (e.g. ketoconazole) or inductors (e.g. carbamazepine, phenytoin, St. John’s Wort)
  • •- Patients who are homozygous for the UGT1A1 and characterized by the presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter ((TA)7TAA). For patients having shown good tolerability of irinotecan in a precedent treatment line according to the investigator´s judgement, the availability of the UGT1A1 result is not mandatory for study inclusion.
  • •- Severe internal disease: insufficiently treated or uncontrolled arterial hypertension, hemoptoe, New York Heart Association (NYHA) grade II or greater congestive heart failure, symptomatic coronary heart disease, myocardial infarction (= 12 months prior to inclusion), serious cardiac arrhythmia requiring medication, peripheral arterial occlusive disease stage II or greater, uncontrolled severe disease
  • •- Patients with a confirmed QTcF > 480 ms, or a history of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome)
  • •- Patients with a history of other malignancies unless having undergone definitive treatment more than 5 years prior to entry into the study and without evidence of recurrent malignant disease; Note: patients with basal cell carcinoma of the skin, superficial carcinoma of the bladder, carcinoma of the prostate with a current PSA < 0.1 ng/ml, or cervical intraepithelial neoplasia within the last 5 years are allowed
  • •- Patients with any other medical, psychiatric or social condition, which in the opinion of the investigator would preclude participation in the trial, pose an undue medical hazard, interfere with the conduct of the trial or interfere with interpretation of the trial results
  • •- Patients with a history of hypersensitivity reactions to compounds of similar chemical or biological composition to resminostat or to any component of the FOLFIRI treatment
  • •- Women who are pregnant or lactating or who are planning on becoming pregnant during the trial or for 90 days after completion of the trial
  • •- Patients with a history of, who were treated for, or who are suspected of having, hepatitis B, hepatitis C or HIV. Patients suspected of having any of these conditions should undergo appropriate evaluations prior to being enrolled in the study
  • •- History or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food
  • •- History of organ transplantation
  • •- Symptomatic brain and/or CNS metastases
  • •- Major surgery within the last 4 weeks
  • •- Patients who are employees at the investigational site, re

研究者

发起方
4SC AG

相似试验

已完成
1/2 期
A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal transplant patients
2024-516577-76-00Centre Hospitalier Universitaire De Nantes10
已完成
1 期
A phase I/IIa study to assess safety, tolerability, pharmacokinetic, pharmacodynamic effects and exploratory efficacy of two doses of AGMG0201 in patients with essential hypertension.Essential HypertensionCardiovascular - Hypertension
ACTRN12617001192370Avance Clinical Pty Ltd24
已完成
不适用
A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjectsautoimmune diseases10003816
NL-OMON42466Omeros Corporation24
进行中（未招募）
1 期
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trialAdvanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based ChemotherapyMedDRA version: 21.0Level: PTClassification code: 10014736Term: Endometrial cancer recurrent Class: 100000004864
CTIS2023-508583-30-00Vall D Hebron Institute Of Oncology58
招募中
2 期
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy
2024-517705-93-00Fundacion Oncosur140